<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250430065545N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-08-14</date_registration>
      <primary_sponsor>Esfahan University of Medical Sciences</primary_sponsor>
      <public_title>Effects of Transcranial Direct Current Stimulation on Athletic Performance</public_title>
      <acronym></acronym>
      <scientific_title>Investigation of the Effects of Transcranial Direct Current Stimulation on Athletic Performance: A Comparison Between Primary Motor Cortex and Dorsolateral Prefrontal Cortex</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-05-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>17</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/83341</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: N/A, Blinding: Double blinded, Placebo: Used, Assignment: Crossover, Purpose: Other, Blinding description: Participant: On one of the intervention days, transcranial direct current stimulation is applied in a non-realistic manner and the participant is unaware of the method of application of the stimulation.
Evaluator: The person evaluating the consequences of the intervention is unaware of the type and location of transcranial direct current stimulation applied to the subjects.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Strength, muscular endurance, and perceived exertion in strength athletes.</hc_freetext>
      <i_freetext>Intervention Group 1: Primary Motor Cortex (M1) Stimulation:Anodal transcranial direct current stimulation (tDCS) over the primary motor cortex (M1).Stimulation parameters: Current intensity of 2 mA for 20 minutes. The anode electrode will be placed over the M1 region (according to the 10-20 EEG system), and the cathode (return) electrode will be placed over the contralateral supraorbital region.Intervention Group 2: Dorsolateral Prefrontal Cortex (DLPFC) Stimulation:Anodal transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex (DLPFC).Stimulation parameters: Current intensity of 2 mA for 20 minutes. The anode electrode will be placed over the DLPFC region, and the cathode (return) electrode will be placed over the contralateral supraorbital region.Intervention Group 3: Sham Stimulation:Sham transcranial direct current stimulation (tDCS).Stimulation parameters: Electrode placement will be similar to one of the active conditions (e.g., M1 or DLPFC, randomly). The current will be applied for a short duration (30 seconds) and then turned off, while the device remains on, to allow the participant to experience the initial sensation of stimulation; however, active stimulation will not continue throughout the 20-minute duration.This study is a randomized, double-blind, crossover clinical trial. Each participant will receive all three intervention conditions (M1 stimulation, DLPFC stimulation, and Sham stimulation) in separate sessions and in a randomized order. A washout period of 2 days will be observed between each intervention session..</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is The decision regarding the sharing of individual participant data (IPD) requires careful consideration of ethical implications, obtaining further informed consent, and establishing a clear protocol for de-identification and controlled data access. Currently, a specific plan for this purpose has not been developed, but the possibility of exploring this after the study's completion, while fully adhering to ethical principles and protecting participant privacy, will be considered.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Mohammad Hossein Shafiezadeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 3, Mah Complex, Pega Alley, Khwarizmi 1st Street, Ghadir Boulevard, Sepahan Shahr, Isfahan</address>
        <city>isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8179918639</zip>
        <telephone>+98 31 3653 1491</telephone>
        <email>shafiezadeh@rehab.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Dr. Navid Taheri</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Room 324, Department of Physiotherapy, School of Rehabilitation Sciences, Isfahan University of Medical Sciences and Health Services, Hezar Jerib St. isfahan</address>
        <city>isfahan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>81746-73461</zip>
        <telephone>+98 31 3792 5049</telephone>
        <email>n_taheri@rehab.mui.ac.ir</email>
        <affiliation>Esfahan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>At least 6 months of experience in resistance training
Right feet dominant</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>30 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>History of musculoskeletal injury in lumbar, hip, or knee
Use of hormonal injection such as steroids in the last 3 months
Use of creatine supplement in the last 1 month</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Rehabilitation</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention Group 1: Primary Motor Cortex (M1) Stimulation:Anodal transcranial direct current stimulation (tDCS) over the primary motor cortex (M1).Stimulation parameters: Current intensity of 2 mA for 20 minutes. The anode electrode will be placed over the M1 region (according to the 10-20 EEG system), and the cathode (return) electrode will be placed over the contralateral supraorbital region.Intervention Group 2: Dorsolateral Prefrontal Cortex (DLPFC) Stimulation:Anodal transcranial direct current stimulation (tDCS) over the dorsolateral prefrontal cortex (DLPFC).Stimulation parameters: Current intensity of 2 mA for 20 minutes. The anode electrode will be placed over the DLPFC region, and the cathode (return) electrode will be placed over the contralateral supraorbital region.Intervention Group 3: Sham Stimulation:Sham transcranial direct current stimulation (tDCS).Stimulation parameters: Electrode placement will be similar to one of the active conditions (e.g., M1 or DLPFC, randomly). The current will be applied for a short duration (30 seconds) and then turned off, while the device remains on, to allow the participant to experience the initial sensation of stimulation; however, active stimulation will not continue throughout the 20-minute duration.This study is a randomized, double-blind, crossover clinical trial. Each participant will receive all three intervention conditions (M1 stimulation, DLPFC stimulation, and Sham stimulation) in separate sessions and in a randomized order. A washout period of 2 days will be observed between each intervention session.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Maximum Voluntary Contraction (MVC): Maximum isometric force produced by the quadriceps femoris muscle. Muscular Endurance: Maximum number of correct repetitions of knee extension exercise with a specific load (30-40% of 1-RM) until complete exhaustion. Rate of Perceived Exertion (RPE): Subjective assessment of an individual's perceived level of difficulty and strain associated with the physical activity performed. Timepoint: Before and immediately after each intervention session (anodal tDCS over M1, anodal tDCS over DLPFC, and sham tDCS). Method of measurement: Maximum Voluntary Contraction (MVC): Using a handheld dynamometer, while the subject is seated on a knee extension machine with the knee flexed at a 90-degree angle. The subject is instructed to extend the knee with maximal effort for 5 seconds. This process is repeated 3 times with a one-minute rest interval, and the highest value is recorded.Muscular Endurance: Using a leg extension machine. Subjects are asked to lift a weight equivalent to 30-40% of their 1-RM until they can no longer perform additional repetitions. The number of completed repetitions is recorded.Rate of Perceived Exertion (RPE): Using the Borg's RPE scale (ranging from 6 to 20), reported by the subject after the muscular endurance test.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Esfahan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-04-30</approval_date>
        <contact_name>Ethics committee of isfahan University of Medical Sciences</contact_name>
        <contact_address>Unit 3, Mah Complex, Pega Alley, Khwarizmi 1st Street, Ghadir Boulevard, Sepahan Shahr, Isfahan isfahan Isfehan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
